Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 February 2024Website:
http://www.altoneuroscience.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 20 min agoDividend
Analysts recommendations
Institutional Ownership
ANRO Latest News
Are you looking for low-cost stocks to add to your portfolio?
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Award finalist by EY. Now in its 38th year, Entrepreneur Of The Year is the preeminent competitive business award for audacious leaders who disrupt markets, revolutionize sectors, and have a transformational impact on lives. Over the past four decades, the program has recognized daring entrepreneurs.
ANRO has experienced strong earnings estimate revisions in the past month and operates within a robust industry.
Alto Neuroscience (ANRO) went public on the NYSE today. CEO Amit Etkin joins Nicole Petallides to give an overview of the company.
Alto Neuroscience announced that it has filed for a proposed initial public offering (IPO) to raise up to $100 million. It plans to list on the NYSE under the symbol ‘ANRO', but no pricing terms were disclosed.
Alto Neuroscience, Inc. has filed for a $100 million IPO to develop treatments for brain and central nervous system conditions, although the final figure may differ. The company's lead candidate, ALTO-100, is in Phase 2 trials for major depressive disorder and post-traumatic stress disorder. The global market for depression treatment is expected to reach $16.8 billion by 2032, with the treatment for PTSD also a large market, driving demand for Alto's drug candidates.
What type of business is Alto Neuroscience?
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
What sector is Alto Neuroscience in?
Alto Neuroscience is in the Healthcare sector
What industry is Alto Neuroscience in?
Alto Neuroscience is in the Biotechnology industry
What country is Alto Neuroscience from?
Alto Neuroscience is headquartered in United States
When did Alto Neuroscience go public?
Alto Neuroscience initial public offering (IPO) was on 02 February 2024
What is Alto Neuroscience website?
https://www.altoneuroscience.com
Is Alto Neuroscience in the S&P 500?
No, Alto Neuroscience is not included in the S&P 500 index
Is Alto Neuroscience in the NASDAQ 100?
No, Alto Neuroscience is not included in the NASDAQ 100 index
Is Alto Neuroscience in the Dow Jones?
No, Alto Neuroscience is not included in the Dow Jones index
When was Alto Neuroscience the previous earnings report?
No data
When does Alto Neuroscience earnings report?
The next expected earnings date for Alto Neuroscience is 29 November 2024